Therapeutic Bispecific Antibodies Development Services
Despite the presence of authorized targeted medications for the treatment of leukemia, a portion of patients still encounter difficulties in achieving effective treatment outcomes. Leukemia therapy can be advanced through the development of bispecific antibodies. Alfa Cytology specializes in analyzing the structure-function relationship of bispecific antibodies and providing targeted modifications to optimize their binding affinity, specificity, and other desired characteristics.
Introduction to Bispecific Antibodies
Bispecific antibodies have been engineered to target two distinct antigens simultaneously, enabling a more precise and efficient approach to combating leukemia cells. Blinatumomab, a CD19/CD3 bispecific antibody developed using bispecific T-cell engager (BiTE) technology, has significantly transformed the therapeutic landscape for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Ongoing clinical trials and research endeavors continue to investigate the vast potential of bispecific antibodies in leukemia therapy.
Fig. 1. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia. (Robinson, H.R. et al., 2018)
Design of Bispecific Antibodies Targeting Leukemia
We provide comprehensive design services for bispecific antibodies that specifically target leukemia cell surface receptors. This innovative approach paves the way for novel treatment strategies for leukemia.
Discovery of Bispecific Antibodies for Leukemia
| CD3/CD19 Bispecific Antibody | We provide services encompassing the design and preparation of bispecific antibodies. By specifically targeting cell surface receptors, such as CD19 and CD20 expressed on precursor and mature B lymphocytes, along with CD3 expressed on T cells, our innovative antibody designs are revolutionizing the treatment approach for adult acute lymphoblastic. |
| CD3/CD123 Bispecific Antibody | By capitalizing on the specific expression of CD3 on T cells and CD123 on acute myelogenous leukemia blast cells, our bispecific antibody design and characterization services provide novel insights for advancing targeted treatment research in acute myelogenous leukemia. |
| CD3/CD33 Bispecific Antibody | We can construct bispecific antibodies that specifically target CD33 and CD3. Our approach involves selecting one scFv domain to bind to CD33 expressed by acute myelogenous leukemia cells, while the other scFv is designed to recognize CD3 on T cells. With our CD3/CD33 bispecific antibody construction service, we provide you with high-quality bispecific antibodies that can significantly accelerate your research into acute myelogenous leukemia treatment. |
Development of Methods for Combination Therapy of Bispecific Antibodies
Our institute provides comprehensive services for the development of combination approaches, aiming to investigate the potential benefits of integrating bispecific antibodies with tyrosine kinase inhibitors or BCL-2 inhibitors in the quest for efficacious therapeutic interventions. Our primary objective revolves around the identification of optimal scenarios for the utilization of these combination therapies. Leveraging our extensive repertoire of inhibitors, we offer a diverse array of combination regimens to enhance the outcomes of CLL.
Bispecific Antibodies Development Process
Design of bispecific antibody
Preparation of bispecific antibody
Antibody optimization
Animal model evaluation
Why Choose Us?
Customized
Solutions
Regulatory
Compliance
Timely
Delivery
Highly
Confidential
Harness the scientific expertise, advanced platform, and tailored services provided by Alfa Cytology to accelerate the development of leukemia-specific bispecific antibodies. Our specialized resources will empower your research and expedite the progress toward effective treatments. Contact us to discuss your specific requirements.
Reference
- Robinson, H.R.; et al. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. The Journal of the American Society of Hematology. 2018, 132(5): 521-532.